Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals

Overview of attention for article published in JAC - Antimicrobial Resistance, April 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)

Mentioned by

twitter: 7 X users

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 24,840 followers.

RT @AntibioticLeeds: @UKCPAPIN @biainfection @ESGAP_ABS @NHSNEY @eopat @NCAS_Aus @CW_Pharmacists

RT @jac_amr: “Dalbavancin is confirmed an optimal therapeutic strategy for the management of ABSSSI, allowing cost savings and improvement…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.